CD8A and cancer: The same accounted for the influence of metastasis: although metastatic cancers harbored higher rates of Ki67+PD1+ CD8 T cells and Tregs (Figure 1C; Supplementary Table 7), excluding all stage IV cancers from location-immune analyses did not change our differential analysis results (Supplementary Table 8).